Patents Issued in July 25, 2019
  • THIOGLYCOLURIL COMPOUND, AND METHOD FOR PRODUCING SAME
    Publication number: 20190225619
    Abstract: A novel monothioglycoluril compound and a novel dithioglycoluril compound. A thioglycoluril compound of the following Formula (1): (wherein X is an oxygen atom or a sulfur atom, and four Rs are each a hydrogen atom, a linear, branched, or cyclic alkyl group having a carbon atom number of 1 to 4, a phenyl group, a naphthyl group, a benzyl group, or a C3-9 alkyl group having at least one ether bond on the main chain).
    Type: Application
    Filed: August 22, 2017
    Publication date: July 25, 2019
    Applicant: NISSAN CHEMICAL CORPORATION
    Inventors: Masahisa ENDO, Gun SON
  • IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES
    Publication number: 20190225620
    Abstract: Compounds of formula I or a stereoisomer or pharmaceutically-acceptable salt thereof, are useful in the modulation of IL-12, IL-23 and/or IFNa, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of formula I are useful for the treatment of inflammatory or autoimmune diseases.
    Type: Application
    Filed: October 2, 2017
    Publication date: July 25, 2019
    Inventors: Steven H. Spergel, Michael E. Mertzman
  • PYRROLOPYRIMIDINES AS CFTR POTENTIATORS
    Publication number: 20190225621
    Abstract: The present invention relates to methods of using compounds of Formula I, wherein R1a, R1b, R2, R3, R4, W, Y, and Z are as described herein, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compound, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sjögren's Syndrome, and other CFTR associated disorders.
    Type: Application
    Filed: April 5, 2019
    Publication date: July 25, 2019
    Inventors: Joseph Walter Strohbach, David Christopher Limburg, John Paul Mathias, Atli Thorarensen, Rajiah Aldrin Denny, Christoph Wolfgang Zapf, Daniel Elbaum, Lori Krim Krim Gavrin, Ivan Viktorovich Efremov
  • Process for the Preparation of Oxymorphone Alkaloid and Oxymorphone Salts
    Publication number: 20190225622
    Abstract: The present invention provides a process for preparing an oxymorphone acid adduct, said process comprising hydrogenating an aqueous solution of 14-hydroxymorphinone and an acid to form a solution of the oxymorphone acid adduct, wherein the hydrogenation is carried out at one or more temperatures greater than 40° C. in the presence of a hydrogenation catalyst and hydrogen gas, wherein the level of 6?-oxymorphol produced is ?3.00 area % as determined by HPLC.
    Type: Application
    Filed: March 25, 2019
    Publication date: July 25, 2019
    Applicant: Johnson Matthey Public Limited Company
    Inventors: Ewart GRANT, Brian HEINRICH, Saroop MATHARU, Nicholas ARCHER
  • SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF
    Publication number: 20190225623
    Abstract: The present invention provides solid forms of compounds useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, methods of producing the same, and methods of using the same in the treatment of ACC-mediated diseases.
    Type: Application
    Filed: December 12, 2018
    Publication date: July 25, 2019
    Inventors: Katy Alexander, John C. Amedio, JR., Selcuk Calimsiz, Michael Geier, Geraldine C. Harriman, Sijun Hu, Jon P. Lawson, Henry Morrison, Kyle Sabourin, Mark E. Scott, Vimal Varghese, Kunal Arvind Varia, Xiaotian Wang, Xiaowei Yang
  • INTERMEDIATES IN THE SYNTHESIS OF CEPHALOSPORIN COMPOUNDS
    Publication number: 20190225624
    Abstract: Described herein are crystalline forms of a compound of formula (III?), including toluene solvates of TATD-CLE, as well as processes for the preparation thereof and use thereof in the preparation of cephalosporin compounds such as ceftolozane.
    Type: Application
    Filed: March 4, 2019
    Publication date: July 25, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Kristos Adrian Moshos, Valdas Jurkauskas, Giovanni Fogliato, Manuel Scanu, You Seok Hwang
  • NITROGEN-CONTAINING MACROCYCLIC CONJUGATES AS RADIOPHARMACEUTICALS
    Publication number: 20190225625
    Abstract: The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.
    Type: Application
    Filed: April 9, 2019
    Publication date: July 25, 2019
    Inventors: Paul Stephen Donnelly, Michelle Therese Ma, Denis Bernard Scanlon
  • ISOSULFAN BLUE, ITS CRYSTALLINE FORM AND PROCESS FOR PREPARATION THEREOF
    Publication number: 20190225626
    Abstract: Provided is an improved process for the preparation N-[4-[[4-(diethyl amino) phenyl](2,5-disulfophenyl)methylene]-2,5-cyclohexadien-1-ylidene]-N-ethylethanaminium inner salt sodium salt (Isosulfan blue) of formula I. It also relates to highly pure novel crystalline form of Isosulfan blue hydrate and its process for the preparation thereof. It also relates to an improved process for the preparation of Isosulfan blue sodium hydrate having not more than 0.2% of desethyl impurity of formula A.
    Type: Application
    Filed: September 6, 2016
    Publication date: July 25, 2019
    Inventors: MANIK REDDY PULLAGURLA, MECHERIL VALSAN NANDA KUMAR, BHASKAR REDDY PITTA, SURESH BABU NAMANA, JAGADEESH BABU RANGISETTY, SADASHIV CHOPPARI
  • NITROGEN-CONTAINING COMPOUND AND COLOR CONVERSION FILM COMPRISING SAME
    Publication number: 20190225627
    Abstract: The present specification relates to a compound containing nitrogen, and a color conversion film, a backlight unit, and a display device, including the same.
    Type: Application
    Filed: November 14, 2017
    Publication date: July 25, 2019
    Applicant: LG CHEM, LTD.
    Inventors: Milim LEE, Seonkyoung LEE, Cheol Jun SONG, Hoyong LEE
  • BETA-LACTAMASE INHIBITORS
    Publication number: 20190225628
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Application
    Filed: January 2, 2019
    Publication date: July 25, 2019
    Inventors: Christopher J. BURNS, Denis DAIGLE, Bin LIU, Daniel McGARRY, Daniel C. PEVEAR, Robert E. Lee TROUT
  • METHOD FOR PREPARING SILAHYDROCARBONS
    Publication number: 20190225629
    Abstract: The present disclosure is directed to a process for preparing silahydrocarbons of formula (I): the process including the step of reacting a compound of formula (II): R1-MX??(II) with a compound of formula (III): as well as to silahydrocarbons prepared by such a process, and to compositions and articles of manufacture containing such silahydrocarbons.
    Type: Application
    Filed: September 27, 2017
    Publication date: July 25, 2019
    Applicant: University of Delaware
    Inventors: Donald Watson, Andrew Cinderella, Bojan Vulovic
  • METHOD FOR PRODUCING N-SILYLAMINOALKYLSILANE COMPOUND
    Publication number: 20190225630
    Abstract: Shown is a method for producing an N-silylaminoalkylsilane compound. The N-silylaminoalkylsilane compound is produced by allowing an aminoalkylsilane compound to react with a monochlorosilane compound in the presence of a tertiary amine compound having an acid dissociation constant (pKa) of 7 or more and a polar surface area (PSA) of 12 ?2 or more. The aminoalkylsilane compound is a compound represented by formula (1), for example. In formula (1), R1 is alkyl having 1 to 5 carbons; R2 is hydrogen, phenyl or 2-aminoethyl; m is 1, 2, 3, 4 or 5; and n is 0, 1 or 2. A reaction is as described in (ZZ) below, for example.
    Type: Application
    Filed: June 6, 2017
    Publication date: July 25, 2019
    Applicant: JNC CORPORATION
    Inventors: Junichi TERASAWA, Chisato TSURUOKA, Toru TANAKA
  • NOVEL DIPHENYLMETHANE PROTECTIVE AGENT
    Publication number: 20190225631
    Abstract: An object of the present invention is to develop a protecting group, which can prevent solidification or insolubilization of a compound by protecting a functional group to achieve easy separation and purification after a reaction.
    Type: Application
    Filed: June 19, 2017
    Publication date: July 25, 2019
    Applicant: SEKISUI MEDICAL CO., LTD.
    Inventors: Shinya YANO, Hideki KUBOTA
  • CYCLIC GERMANIUM COMPOUNDS AND APPLICATIONS THEREOF
    Publication number: 20190225632
    Abstract: The present disclosure provides a new series of compounds exhibiting high fluorescence quantum yields in the solid state. In one embodiment, the compounds include a series of 2,3,4,5-tetraphenylgermoles with the same or different 1,1-substituents. In another embodiment, substituted germafluorenes, germa-fluoresceins/rhodamines, and germapins are described. These germanium heterocycles possess ideal photophysical and thermostability properties, which makes them excellent candidates for chemical or biological sensors, host materials for electroluminescent devices and solar cells, and emissive and/or electron-transport layer components in organic light emitting diode devices.
    Type: Application
    Filed: March 29, 2019
    Publication date: July 25, 2019
    Inventors: Janet Braddock-Wilking, Teresa Lynn Bandrowsky, James Bryan Carroll, II
  • DNA ALKYLATING AGENTS
    Publication number: 20190225633
    Abstract: Provided herein are compounds of formula I: wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.
    Type: Application
    Filed: March 28, 2019
    Publication date: July 25, 2019
    Applicant: OBI PHARMA, INC.
    Inventors: Jian-Xin Duan, Yeyu Cao, Xiaohong Cai, Hailong Jiao, Jing Yuan Ma, Mark Matteucci
  • NAHLSGEN OPTICAL RESOLUTION METHOD
    Publication number: 20190225634
    Abstract: Provided is a method for separating the four optical isomers of Nahlsgen.
    Type: Application
    Filed: September 12, 2017
    Publication date: July 25, 2019
    Applicant: KYOTO UNIVERSITY
    Inventors: Jun HIRATAKE, Bunta WATANABE, Ryuzo YOSHIOKA, Hideaki ISHIDA
  • METAL COMPLEXES CONTAINING SUBSTITUTED PYRIDINE LIGANDS
    Publication number: 20190225635
    Abstract: Novel compounds with substituted pyridine ligands are disclosed, which can be used as emitters in an electroluminescent device. These novel complexes can provide highly saturated color and long lifetime, and good device performance. Also disclosed are an electroluminescent device and a formulation.
    Type: Application
    Filed: January 18, 2019
    Publication date: July 25, 2019
    Inventor: Chuanjun Xia
  • ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND
    Publication number: 20190225636
    Abstract: An organometallic compound represented by Formula 1: wherein, in Formula 1, groups and variables are the same as defined in the specification.
    Type: Application
    Filed: January 22, 2019
    Publication date: July 25, 2019
    Inventors: Hyejin Bae, Changho Noh, Eunsuk Kwon, Sangmo Kim, Minsik Min, Sangho Park, Virendra Kumar RAI, Jhunmo Son, Yongsik Jung
  • PRODUCTION OF BIOMASS IN ULTRA HIGH DENSITY PLANTATIONS
    Publication number: 20190225637
    Abstract: The present application relates to methods for the production of plant material suitable for the extraction and purification of saponins, through plantations of clone plants of defined chemotype, including ultrahigh density plantations of Quillaja saponaria Molina, and methods to increase the recovery of saponins by solid/liquid extraction of the harvested plant material.
    Type: Application
    Filed: September 26, 2016
    Publication date: July 25, 2019
    Inventors: Leandro PADILLA IGLESIAS, Javier GONZALEZ CASTRO, Vladimir ARANGUIZ ARZE-VARGAS, Rodrigo OTERO PEREDO
  • ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS
    Publication number: 20190225638
    Abstract: The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-1 to a ligand in a mammal, such as a human. Furthermore, the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-1 to a ligand in a mammal, such as a human.
    Type: Application
    Filed: July 9, 2017
    Publication date: July 25, 2019
    Applicant: GALECTO BIOTECH AB
    Inventors: Fredrik ZETTERBERG, Hakon LEFFLER, Ulf NILSSON
  • PROCESS FOR THE PREPARATION OF DIOSMIN
    Publication number: 20190225639
    Abstract: Provided is a process for the preparation of diosmin from hesperidin. The process involves the oxidation of acylated hesperidin with iodine or bromine in a C2-C4 carboxylic acid medium and subsequent treatment with an inorganic base to partially neutralize the acidic media. The process allows obtaining diosmin with low iodine or bromine content, avoiding the use of organic solvents.
    Type: Application
    Filed: April 2, 2019
    Publication date: July 25, 2019
    Applicant: INTERQUIM, S.A.
    Inventor: Francisco Javier LÓPEZ CREMADES
  • KETOLIDES HAVING ANTIBACTERIAL ACTIVITY
    Publication number: 20190225640
    Abstract: The present invention relates to ketolide compounds of Formula I. The compounds have good anti-microbial activities, reduced inhibition of cytochrome P4503A4 (CYP3A4), and acceptable safety of co-administration of other drugs. The present invention also relates to a pharmaceutical composition comprising compounds of Formula I and the method of treating anti-microbial infection by administering the compounds. Oral administration is a preferred route of administration.
    Type: Application
    Filed: March 28, 2019
    Publication date: July 25, 2019
    Inventors: Lociuro SERGIO, Khalid ISLAM
  • Crystal Forms of Beta-Nicotinamide Mononucleotide
    Publication number: 20190225641
    Abstract: The invention relates to crystalline forms of a ?-nicotinamide mononucleotide, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to preparations suitable for nutraceutical, veterinary, and agriculturally-relevant uses.
    Type: Application
    Filed: March 28, 2019
    Publication date: July 25, 2019
    Inventors: Andrew Carr, Philippe Fernandes, David J. Livingston
  • CRYSTAL OF CYTIDINE DIPHOSPHATE CHOLINE AND PRODUCTION METHOD THEREOF
    Publication number: 20190225642
    Abstract: An object of the present invention is to provide a crystal of cytidine diphosphate choline which contains no methanol and has improved powder properties, and a production method thereof. According to the present invention, the crystal of cytidine diphosphate choline which contains no methanol and has improved powder properties can be obtained by precipitating the crystal of cytidine diphosphate choline in an aqueous solution in which cytidine diphosphate choline is dissolved, collecting the precipitated crystal of cytidine diphosphate choline, and washing the collected crystal of cytidine diphosphate choline with an aqueous solution containing an organic solvent other than methanol in which a water content is 5% to 50% by volume.
    Type: Application
    Filed: October 6, 2017
    Publication date: July 25, 2019
    Applicant: KYOWA HAKKO BIO CO., LTD.
    Inventor: Kazunari FUKUMOTO
  • NOVEL NUCLEOSIDE ANALOGS AND USE THEREOF IN THERAPEUTIC TREATMENT
    Publication number: 20190225643
    Abstract: The present disclosure is directed to novel nucleoside analog compounds and methods for treating diseases characterized by high expression levels of adenosine kinase (ADK).
    Type: Application
    Filed: April 14, 2017
    Publication date: July 25, 2019
    Applicant: CORNELL UNIVERSITY
    Inventors: Ethel CESARMAN, Utthara NAYAR, J. David WARREN, Jouliana SADEK
  • MRNA CAP ANALOGS AND METHODS OF MRNA CAPPING
    Publication number: 20190225644
    Abstract: The present disclosure relates to cap analogs, which can result in high levels of capping efficiency and transcription and improved translation efficiencies. The present disclosure also relates to methods useful for preparing cap analogs and using mRNA species containing such analogs, as well as kits containing the novel cap analogs.
    Type: Application
    Filed: October 17, 2016
    Publication date: July 25, 2019
    Inventors: Gabor BUTORA, Matthew STANTON, Thomas STEELE
  • Method for Preparing a Complete Protein and Uses Thereof
    Publication number: 20190225645
    Abstract: A method of preparing a complete protein by the addition of essential amino acids to an incomplete protein can include calculating an amount of each essential amino acid to be added to an incomplete protein and adding the calculated amount of each essential amino acid to the incomplete protein. The calculations can be done using a particular equation, described herein.
    Type: Application
    Filed: January 17, 2019
    Publication date: July 25, 2019
    Inventor: Arthur Merrill Zemach
  • Method for Purifying Recombinant Protein
    Publication number: 20190225646
    Abstract: Disclosed is a method for purifying a recombinant protein of interest from a recombinant cell expressing intracellularly the recombinant protein as an insoluble matter, comprising treating the recombinant cell under conditions where a protein derived from a host cell dissolves in a first aprotic polar solvent to which an inorganic salt is added or not but the recombinant protein does not dissolve, removing a first soluble fraction, and then treating the resulting first insoluble fraction under conditions where the recombinant protein dissolves in a second aprotic polar solvent to which an inorganic salt is added.
    Type: Application
    Filed: October 3, 2017
    Publication date: July 25, 2019
    Applicant: Spiber Inc.
    Inventor: Toshimasa Homma
  • ANTIGENIC PEPTIDES FOR THE DIAGNOSIS, THERAPY MONITORING AND/OR TREATMENT OF PSORIASIS VULGARIS
    Publication number: 20190225647
    Abstract: The present invention relates to peptides with a conserved amino acid motif and pharmaceutical compositions comprising these peptides. The present invention further relates to the use of the peptides as biomarker, the medical use of the peptides, in particular in the diagnosis, prevention, monitoring and/or treatment of Psoriasis. The present invention relates to complexes of the peptides of the invention with HLA-C monomers or multimers and their use as biomarker and their medical uses, in particular in the treatment of Psoriasis and in monitoring such treatment. The present invention furthermore relates to means and methods for the prevention and/or treatment of Psoriasis, that comprise inhibiting or blocking the interaction of TCR and HLA-C.
    Type: Application
    Filed: June 30, 2016
    Publication date: July 25, 2019
    Inventors: Jörg Christoph PRINZ, Klaus DORNMAIR
  • BIOLOGICALLY ACTIVE PEPTIDES
    Publication number: 20190225648
    Abstract: A peptide or peptide derivative comprising: (i) WDLYFEIVW (SEQ ID NO:1); or (ii) a variant amino acid sequence comprising one, two, three or four L-amino acid substitutions in WDLYFEIVW (SEQ ID NO: 1); or (iii) the retro-inverso variant of the peptide or peptide derivative of either one of parts (i) and (ii), wherein said peptide or peptide derivative has procoagulant activity. A peptide or peptide derivative comprising: (i) an amino acid sequence comprising imfwydcye; or (ii) a variant amino acid sequence comprising one, two, three, four, five or six amino acid substitutions in imfwydcye, wherein said peptide or peptide derivative has procoagulant activity.
    Type: Application
    Filed: March 20, 2019
    Publication date: July 25, 2019
    Inventors: Friedrich Scheiflinger, Michael Dockal
  • AGENTS THAT ACTIVATE CD47 AND THEIR USE IN THE TREATMENT OF INFLAMMATION
    Publication number: 20190225649
    Abstract: Disclosed are agents activating CD47 and their use in the treatment of inflammation, in particular non-resolving low grade inflammation, characterized by chronic MP infiltration, such as age-related macular degeneration. Also disclosed are pharmaceutical compositions, medicaments and kits including the agents.
    Type: Application
    Filed: May 10, 2017
    Publication date: July 25, 2019
    Inventors: Florian SENNLAUB, Michael HOUSSET, Xavier GUILLONNEAU, José-Alain SAHEL, Philippe KAROYAN
  • PEPTIDOMIMETIC MACROCYCLES AND USE THEREOF IN REGULATING HIF1ALPHA
    Publication number: 20190225650
    Abstract: The present invention provides peptidomimetic macrocycles capable of regulating HIF1? and methods of using such macrocycles for the treatment of diseases.
    Type: Application
    Filed: January 30, 2019
    Publication date: July 25, 2019
    Inventors: Vincent GUERLAVAIS, Noriyuki KAWAHATA, Huw M. NASH, Carl ELKIN, Eric FEYFANT
  • COMPOUNDS FOR INDUCING TISSUE FORMATION AND USES THEREOF
    Publication number: 20190225651
    Abstract: The present disclosure provides a cyclic peptide, or a variant or analog thereof, or a cyclic peptidomimetic, with between 10 and 35 amino acids, having a growth factor receptor-binding capability and comprising a peptide with four amino acids PEP1; wherein PEP1 is selected from the group consisting of SAIS, SSLS, NAIS, SATS, SPIS, EPIS, SPIN, KPLS, EPLP, EPLT, SNIT, RSVK and RPVQ.
    Type: Application
    Filed: August 25, 2016
    Publication date: July 25, 2019
    Inventor: Omar F. ZOUANI
  • GENERATION OF PEPTIDES
    Publication number: 20190225652
    Abstract: The present disclosure relates generally to generation of a recombinant enzyme with cyclization activity and its use for generating cyclic peptides as well as linear peptide conjugates.
    Type: Application
    Filed: September 23, 2016
    Publication date: July 25, 2019
    Inventors: Karen Sandra Harris, Marilyn Anne Anderson, Thomas Matthew Alcorn Shafee, Thomas Durek, Mark Jackson, David Craik
  • CAGED CELL PENETRATING PEPTIDE-POLYMER CONJUGATES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
    Publication number: 20190225653
    Abstract: The caged cell-penetrating peptide (cCPP) conjugates of this invention are ideal for intracellular delivery of a broad variety of cargoes including various nanoparticle pharmaceutical carriers (liposomes, micelles, microparticles, nanoparticles, polymer-conjugates). The conjugates comprise a detectable agent or a therapeutic agent, and the conjugates provide a novel strategy for site-specific delivery of the same to appropriate tissues in the subject. Versatile application of the conjugates in diagnostics and imaging is described.
    Type: Application
    Filed: November 30, 2018
    Publication date: July 25, 2019
    Inventors: Ayelet DAVID, Gonen ASHKENASY, Yosi SHAMAY
  • METHODS AND COMPOSITIONS FOR DENGUE VIRUS VACCINES
    Publication number: 20190225654
    Abstract: The present invention provides compositions and methods of use comprising a chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone, which comprises amino acid substitutions that introduce an epitope that is recognized by an antibody from a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone.
    Type: Application
    Filed: August 20, 2018
    Publication date: July 25, 2019
    Inventors: William Messer, Ralph Baric, Aravinda de Silva, Boyd Yount
  • FACTOR H BINDING PROTEIN VARIANTS AND METHODS OF USE THEREOF
    Publication number: 20190225655
    Abstract: Variant factor H binding proteins that can elicit antibodies that are bactericidal for at least one strain of Neisseria meningitidis, compositions comprising such proteins, and methods of use of such proteins, are provided.
    Type: Application
    Filed: February 28, 2019
    Publication date: July 25, 2019
    Inventor: Peter T. Beernink
  • ALPHA-HEMOLYSIN VARIANTS WITH ALTERED CHARACTERISTICS
    Publication number: 20190225656
    Abstract: Described herein are variants of alpha-hemolysin having at least one mutation selected from T12R, T12K, N17R, N17K or combinations of T12 and N17 mutations. The variants in some embodiments may further comprise H144A. The ?-hemolysin variants have a decreased time to thread.
    Type: Application
    Filed: April 4, 2019
    Publication date: July 25, 2019
    Applicant: Genia Technologies, Inc.
    Inventors: Michael Dorwart, Daniel Korenblum
  • METHOD FOR THE PRODUCTION OF HAPLOID AND SUBSEQUENT DOUBLED HAPLOID PLANTS
    Publication number: 20190225657
    Abstract: The present disclosure provides a modified CenH3 protein that, when present in a plant, allows the plant to be used as a haploid inducer line for plant breeding purposes. Polynucleotides encoding such modified CenH3 proteins, chimeric genes and vectors comprising such polynucleotides, host cells, and plants comprising such polynucleotides, chimeric genes or vectors are also provided. Additionally, methods for making such plants as well as methods for producing haploid or doubled haploid plants using such plants are disclosed.
    Type: Application
    Filed: May 19, 2017
    Publication date: July 25, 2019
    Applicant: Keygene N.V.
    Inventors: Rik Hubertus Martinus OP DEN CAMP, Peter Johannes VAN DIJK, Anthony GALLARD
  • PEPTIBODIES, COMPOSITIONS THEREOF, AND METHODS OF TREATING ATRIAL FIBRILLATION
    Publication number: 20190225658
    Abstract: Described herein are peptibodies that can contain a TertiapinQ peptide, formulations thereof, and uses thereof. In some embodiments, the peptibody can include a first monomer and a second monomer, wherein each monomer can include an Fc polypeptide, a first TertiapinQ peptide, wherein the N-terminus of the first TertiapinQ peptide can be linked to the C-terminus of the Fc polypeptide via a first linker, and wherein the first monomer and the second monomer can be attached via a disulfide bridge between the Fc polypeptide of the first monomer and the Fc polypeptide of the second monomer. The compositions and formulations thereof can be used to treat atrial fibrillation.
    Type: Application
    Filed: March 29, 2019
    Publication date: July 25, 2019
    Applicant: University of South Florida
    Inventors: SAMI FOUAD NOUJAIM, MICHAEL TENG
  • ODORANT RECEPTOR CO-RECEPTOR
    Publication number: 20190225659
    Abstract: Provided is an insect odorant receptor co-receptor that exhibits excellent detection sensitivity to an odorous substance when bound to an odorant receptor to form an odorant receptor complex. The odorant receptor co-receptor includes a first amino acid sequence and a second amino acid sequence subsequently to the farthest carboxyl-terminal amino acid residue of the first amino acid sequence.
    Type: Application
    Filed: September 26, 2017
    Publication date: July 25, 2019
    Inventors: Yasuhiko TAKAHASHI, Tomoyuki TAKAKU
  • METHOD OF TREATING AND PREVENTING OCULAR ANGIOGENESIS
    Publication number: 20190225660
    Abstract: The present invention provides methods for inhibiting ocular angiogenesis, vascular leakage, and edema. The methods comprise administering to a subject an agent which comprises a caveolin scaffolding domain. The present invention further encompasses methods of treating and preventing ophthalmic conditions that are associated with ocular angiogenesis, vascular leakage, or edema.
    Type: Application
    Filed: October 2, 2018
    Publication date: July 25, 2019
    Inventor: William C. SESSA
  • Compositions and Methods for Vascular Protection Against Reperfusion Injury After Myocardial Ischemia
    Publication number: 20190225661
    Abstract: As described herein, the present invention features compositions comprising an HGF/IgG complex and methods of using such compositions to reduce ischemic reperfusion injury.
    Type: Application
    Filed: February 7, 2019
    Publication date: July 25, 2019
    Applicant: The University of Vermont and State Agriculture College
    Inventor: JEFFREY SPEES
  • Therapeutic Agents for Neurological and Psychiatric Disorders
    Publication number: 20190225662
    Abstract: The present invention relates to the field of disorders of the central nervous system, in particular neurological and psychiatric disorders, and the prevention and/or treatment thereof. In particular, the present invention relates to the finding that soluble amyloid precursor protein ? (sAPP?) presents a particular binding site, which allows for binding to the GABABR1a receptor, thereby causing an agonistic effect through specific binding to Sushi domain 1 of GABABR1a. As a result, the frequencies of excitatory and inhibitory postsynaptic currents are reduced. Accordingly, the invention provides compounds able to interfere with the association of sAPP? with Sushi domain 1 of GABABR1a and as such with selective impairment of GABABR1a beneficial in neurological and psychiatric disorders. The invention as well provides methods and (high content) screening assays for the production of said compounds.
    Type: Application
    Filed: July 14, 2017
    Publication date: July 25, 2019
    Applicants: VIB VZW, Katholieke Universiteit Leuven, K.U.Leuven R&D
    Inventors: Joris DE WIT, Heather RICE, Bart DE STROOPER
  • Discovery of Cationic Nonribosomal Peptides as Gram-Negative Antibiotics Through Global Genome Mining
    Publication number: 20190225663
    Abstract: Certain embodiments of the invention pertain to pharmaceutical compositions comprising a cationic nonribosomal peptide (CNRP) or a salt thereof. Certain other embodiments of the invention pertain to methods of treating a bacterial infection in a subject by administering to the subject a CNRP or a salt thereof.
    Type: Application
    Filed: January 23, 2019
    Publication date: July 25, 2019
    Inventors: PEI-YUAN QIAN, YONGXIN LI, ZHENG ZHONG, WEIPENG ZHANG
  • ANTAGONISTS OF ACTIVIN-ACTRIIA AND USES FOR INCREASING RED BLOOD CELL LEVELS
    Publication number: 20190225664
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: September 4, 2018
    Publication date: July 25, 2019
    Inventors: Matthew L. Sherman, Jasbir Seehra, Niels Borgstein
  • VARIANT TYPE III INTERFERONS AND SYNTHEKINES
    Publication number: 20190225665
    Abstract: Compositions and methods are provided relating to Type III interferons.
    Type: Application
    Filed: September 29, 2017
    Publication date: July 25, 2019
    Inventors: Juan Luis Mendoza, Kenan Christopher Garcia
  • Targeted Therapeutic Lysosomal Enzyme Fusion Proteins and Uses Thereof
    Publication number: 20190225666
    Abstract: The present invention relates in general to therapeutic fusion proteins useful to treat lysosomal storage diseases and methods for treating such diseases. Exemplary therapeutic fusion proteins comprise a lysosomal enzyme, a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. Also provided are compositions and methods for treating Mucopolysaccharidosis Type IIIB (Sanfilippo B Syndrome), comprising a targeted therapeutic fusion protein comprising alpha-N-acetylglucosaminidase (Naglu), a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide.
    Type: Application
    Filed: April 8, 2019
    Publication date: July 25, 2019
    Inventors: Mika Aoyagi-Scharber, Teresa Margaret Christianson, Melita Dvorak-Ewell, Daniel J. Wendt, Shinong Long, Jonathan LeBowitz, Daniel Solomon Gold
  • INDUCIBLE CASPASES AND METHODS FOR USE
    Publication number: 20190225667
    Abstract: The disclosure provides inducible caspase polypeptides, compositions comprising inducible caspase polypeptides and sequences encoding the same, cells modified to express the polypeptides and compositions of the disclosure, as well as methods of making and methods of using same for adoptive cell therapy.
    Type: Application
    Filed: October 6, 2017
    Publication date: July 25, 2019
    Inventors: Eric M. OSTERTAG, Devon SHEDLOCK
  • HUMAN-CD123-TARGETING CHIMERIC RECEPTOR LIGAND AND APPLICATION THEREOF
    Publication number: 20190225668
    Abstract: The present invention relates to a human CD123-targeting chimeric receptor ligand, comprising an IL-3 molecule-based CD123 binding domain, a transmembrane region, and an intracellular signaling domain. The present invention provides a T cell modified by the human CD123-targeting chimeric receptor ligand and capable of specifically binding with CD123 on tumor cell surfaces, thereby having specific cytotoxicity on tumor cells. The present invention further relates to an application of the human CD123-targeting chimeric receptor ligand and an immune effector cell thereof in preparing an anti-tumor immunotherapy drug.
    Type: Application
    Filed: August 31, 2017
    Publication date: July 25, 2019
    Applicant: Nanjing Legend Biotech Co., Ltd.
    Inventors: Qiuchuan Zhuang, Xiaohu Fan, Lei Yang, Pingyan Wang